Cargando…

Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial

BACKGROUND: A paucity of strategies exist for extensive-stage small cell lung cancer (ES-SCLC) patients who fail the first-line chemotherapy. Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), which has been demonstrated t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Quan, Xu, Juan-Ying, Xu, Ye-Hong, Chen, Meng, Deng, Li-Chun, Wu, Jian-Ping, Zhou, Tong, Zhang, Li-Qin, Tan, Jie, Pu, Xing-Xiang, Shang, Yu-Long, Hua, Jun, Li, Yuan-Qin, Cai, Wei, Gu, Yu-Lan, Peng, Xing-Chen, Chan, Po-Chung, Jabbour, Salma K., Nam, Hae-Seong, Hua, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186180/ https://www.ncbi.nlm.nih.gov/pubmed/35693282 http://dx.doi.org/10.21037/tlcr-22-313

Ejemplares similares

Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
por: Xu, Yanjun, et al.
Publicado: (2019)

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study
por: Zhao, Shen, et al.
Publicado: (2020)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial
por: Teng, Fei, et al.
Publicado: (2022)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
por: Li, Li-Hua, et al.
Publicado: (2022)

“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
por: Wang, Mingqi, et al.
Publicado: (2021)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
por: Li, Ling, et al.
Publicado: (2018)

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
por: He, Zhen, et al.
Publicado: (2021)

Apatinib in Combination with S‐1 as First‐Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single‐Arm, Phase II Trial
por: Zhou, Na, et al.
Publicado: (2020)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
por: Li, Ling, et al.
Publicado: (2020)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
por: Zhang, Yan, et al.
Publicado: (2022)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
por: Qiu, Hu, et al.
Publicado: (2022)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
por: Li, Xin, et al.
Publicado: (2022)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study
por: Wang, Chenchen, et al.
Publicado: (2021)

A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix
por: Chen, Chao, et al.
Publicado: (2019)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
por: Peng, Hong, et al.
Publicado: (2016)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
por: Xu, Yinghui, et al.
Publicado: (2022)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
por: Wei, Qing, et al.
Publicado: (2020)

Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial
por: Jiang, Wen, et al.
Publicado: (2023)

Apatinib mesylate tablet in the treatment of advanced malignant melanoma
por: Yang, Lingge, et al.
Publicado: (2018)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients
por: Yao, Hui, et al.
Publicado: (2021)

Apatinib inhibits tumor growth and angiogenesis in PNET models
por: Wu, Shan, et al.
Publicado: (2018)

Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway
por: Zhang, Hua, et al.
Publicado: (2018)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial
por: Xu, Zhiyuan, et al.
Publicado: (2021)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study
por: Nie, Caiyun, et al.
Publicado: (2021)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
por: Yuan, Li, et al.
Publicado: (2023)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
por: Song, Zhengbo, et al.
Publicado: (2022)

Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor
por: Luo, Hui-Qin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gcgaq4f5n33t75fvlm8tgqdbpf